Evidence map›Paper›PMID 26025781›Full record

ArticleThe international journal of neuropsychopharmacology2015

The Female Encounter Test: A Novel Method for Evaluating Reward-Seeking Behavior or Motivation in Mice.

Yukio Ago, Shigeru Hasebe, Saki Nishiyama, Satoshi Oka, Yusuke Onaka, Hitoshi Hashimoto, Kazuhiro Takuma, Toshio Matsuda

Open access · goldAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yukio AgoLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Shigeru HasebeLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Saki NishiyamaLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Satoshi OkaLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Yusuke OnakaLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Hitoshi HashimotoLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Kazuhiro TakumaLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma).
Toshio MatsudaLaboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Ago, Mr Hasebe, Ms Nishiyama, Mr Oka, Mr Onaka, Drs Takuma, and Matsuda); Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan (Dr Hashimoto); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Suita, Osaka, Japan (Drs Hashimoto and Matsuda); Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan (Dr Takuma). matsuda@phs.osaka-u.ac.jp.
Chiba University · JPKanazawa University · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReduced motivation is an important marker of psychiatric disorders, including depression. We describe the female encounter test, a novel method of evaluating reward-seeking behavior in mice.

methodsThe test apparatus consists of three open chambers, formed with partitions that allow the animal to move freely from one chamber to another. A test male mouse is habituated in the apparatus, and subsequently a female and male mouse are introduced into a wire-mesh box in the left and right chamber, respectively. The time the test male mouse spends in the female or male area is measured for 10 min.

resultsAll six strains of mice tested showed a significant preference for female encounters. The preference was observed in 7-30-week-old mice. The preference was blocked by castration of the resident male test mouse, and was not affected by the phase of the menstrual cycle of the female intruder. The preference was impaired in mouse models of depression, including social isolation-reared, corticosterone-treated, and lipopolysaccharide-treated mice. The impairment was alleviated by fluvoxamine in isolation-reared and lipopolysaccharide-treated mice, and it was improved by the metabotropic glutamate 2/3 receptor antagonist LY341495 in corticosterone-treated mice. Encounter with a female, but not male, mouse increased c-Fos expression in the nucleus accumbens shell of test male mice. Furthermore, both the preference and encounter-induced increases in c-Fos expression were blocked by dopamine D1 and D2 receptor antagonists.

conclusionsThese findings indicate that motivation in adult male mice can be easily evaluated by quantitating female encounters.

Indexed as

MotivationPsychological TestsRewardSocial BehaviorAmino AcidsAnimalsAntidepressive Agents, Second-GenerationCastrationChoice BehaviorCorticosteroneDepressive DisorderDisease Models, AnimalEquipment DesignEstrous CycleExcitatory Amino Acid AntagonistsFemaleAmino AcidsAntidepressive Agents, Second-GenerationCorticosteroneExcitatory Amino Acid AntagonistsFluvoxamineLipopolysaccharidesLY 341495XanthenesDepression modeldopamineencounter testnucleus accumbenssexual motivation

Identifiers

PMID26025781
PMCPMC4756727
OpenAlexW2105231534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.